Your browser doesn't support javascript.
loading
Broadly neutralizing HIV antibodies define a glycan-dependent epitope on the prefusion conformation of gp41 on cleaved envelope trimers.
Falkowska, Emilia; Le, Khoa M; Ramos, Alejandra; Doores, Katie J; Lee, Jeong Hyun; Blattner, Claudia; Ramirez, Alejandro; Derking, Ronald; van Gils, Marit J; Liang, Chi-Hui; Mcbride, Ryan; von Bredow, Benjamin; Shivatare, Sachin S; Wu, Chung-Yi; Chan-Hui, Po-Ying; Liu, Yan; Feizi, Ten; Zwick, Michael B; Koff, Wayne C; Seaman, Michael S; Swiderek, Kristine; Moore, John P; Evans, David; Paulson, James C; Wong, Chi-Huey; Ward, Andrew B; Wilson, Ian A; Sanders, Rogier W; Poignard, Pascal; Burton, Dennis R.
Affiliation
  • Falkowska E; Department of Immunology and Microbial Science, The Scripps Research Institute, La Jolla, CA 92037, USA; International AIDS Vaccine Initiative, Neutralizing Antibody Center, The Scripps Research Institute, La Jolla, CA 92037, USA; Center for HIV/AIDS Vaccine Immunology and Immunogen Discovery, The S
  • Le KM; Department of Immunology and Microbial Science, The Scripps Research Institute, La Jolla, CA 92037, USA; International AIDS Vaccine Initiative, Neutralizing Antibody Center, The Scripps Research Institute, La Jolla, CA 92037, USA; Center for HIV/AIDS Vaccine Immunology and Immunogen Discovery, The S
  • Ramos A; Department of Immunology and Microbial Science, The Scripps Research Institute, La Jolla, CA 92037, USA; International AIDS Vaccine Initiative, Neutralizing Antibody Center, The Scripps Research Institute, La Jolla, CA 92037, USA.
  • Doores KJ; Department of Immunology and Microbial Science, The Scripps Research Institute, La Jolla, CA 92037, USA; International AIDS Vaccine Initiative, Neutralizing Antibody Center, The Scripps Research Institute, La Jolla, CA 92037, USA; Department of Infectious Diseases, King's College London School of Me
  • Lee JH; International AIDS Vaccine Initiative, Neutralizing Antibody Center, The Scripps Research Institute, La Jolla, CA 92037, USA; Center for HIV/AIDS Vaccine Immunology and Immunogen Discovery, The Scripps Research Institute, La Jolla, CA 92037, USA; Department of Integrative Structural and Computationa
  • Blattner C; International AIDS Vaccine Initiative, Neutralizing Antibody Center, The Scripps Research Institute, La Jolla, CA 92037, USA; Center for HIV/AIDS Vaccine Immunology and Immunogen Discovery, The Scripps Research Institute, La Jolla, CA 92037, USA; Department of Integrative Structural and Computationa
  • Ramirez A; Department of Immunology and Microbial Science, The Scripps Research Institute, La Jolla, CA 92037, USA.
  • Derking R; Department of Medical Microbiology, Academic Medical Center, University of Amsterdam, 1105 AZ Amsterdam, The Netherlands.
  • van Gils MJ; Department of Medical Microbiology, Academic Medical Center, University of Amsterdam, 1105 AZ Amsterdam, The Netherlands.
  • Liang CH; Department of Immunology and Microbial Science, The Scripps Research Institute, La Jolla, CA 92037, USA; International AIDS Vaccine Initiative, Neutralizing Antibody Center, The Scripps Research Institute, La Jolla, CA 92037, USA; Center for HIV/AIDS Vaccine Immunology and Immunogen Discovery, The S
  • Mcbride R; Departments of Cell and Molecular Biology and Chemical Physiology, The Scripps Research Institute, La Jolla, CA 92037, USA.
  • von Bredow B; Department of Pathology and Laboratory Medicine, University of Wisconsin, Madison, Wisconsin 53711, USA.
  • Shivatare SS; Genomics Research Center, Academia Sinica, Nankang, Taipei 115, Taiwan.
  • Wu CY; Genomics Research Center, Academia Sinica, Nankang, Taipei 115, Taiwan.
  • Chan-Hui PY; Theraclone Sciences, Inc., Seattle, Washington 98104, USA.
  • Liu Y; Glycosciences Laboratory, Department of Medicine, Imperial College London, London W12 ONN, UK.
  • Feizi T; Glycosciences Laboratory, Department of Medicine, Imperial College London, London W12 ONN, UK.
  • Zwick MB; Department of Immunology and Microbial Science, The Scripps Research Institute, La Jolla, CA 92037, USA.
  • Koff WC; International AIDS Vaccine Initiative, New York, NY 10038, USA.
  • Seaman MS; Beth Israel Deaconess Medical Center, Center for Virology and Vaccine Research, Boston, MA, 02215, USA.
  • Swiderek K; Theraclone Sciences, Inc., Seattle, Washington 98104, USA.
  • Moore JP; Weill Medical College of Cornell University, New York, NY 10004, USA.
  • Evans D; Department of Pathology and Laboratory Medicine, University of Wisconsin, Madison, Wisconsin 53711, USA.
  • Paulson JC; Department of Integrative Structural and Computational Biology, The Scripps Research Institute, La Jolla, CA 92037, USA.
  • Wong CH; Genomics Research Center, Academia Sinica, Nankang, Taipei 115, Taiwan.
  • Ward AB; International AIDS Vaccine Initiative, Neutralizing Antibody Center, The Scripps Research Institute, La Jolla, CA 92037, USA; Center for HIV/AIDS Vaccine Immunology and Immunogen Discovery, The Scripps Research Institute, La Jolla, CA 92037, USA; Department of Integrative Structural and Computationa
  • Wilson IA; International AIDS Vaccine Initiative, Neutralizing Antibody Center, The Scripps Research Institute, La Jolla, CA 92037, USA; Center for HIV/AIDS Vaccine Immunology and Immunogen Discovery, The Scripps Research Institute, La Jolla, CA 92037, USA; Department of Integrative Structural and Computationa
  • Sanders RW; Department of Medical Microbiology, Academic Medical Center, University of Amsterdam, 1105 AZ Amsterdam, The Netherlands; Weill Medical College of Cornell University, New York, NY 10004, USA.
  • Poignard P; Department of Immunology and Microbial Science, The Scripps Research Institute, La Jolla, CA 92037, USA; International AIDS Vaccine Initiative, Neutralizing Antibody Center, The Scripps Research Institute, La Jolla, CA 92037, USA.
  • Burton DR; Department of Immunology and Microbial Science, The Scripps Research Institute, La Jolla, CA 92037, USA; International AIDS Vaccine Initiative, Neutralizing Antibody Center, The Scripps Research Institute, La Jolla, CA 92037, USA; Center for HIV/AIDS Vaccine Immunology and Immunogen Discovery, The S
Immunity ; 40(5): 657-68, 2014 May 15.
Article in En | MEDLINE | ID: mdl-24768347
ABSTRACT
Broadly neutralizing HIV antibodies are much sought after (a) to guide vaccine design, both as templates and as indicators of the authenticity of vaccine candidates, (b) to assist in structural studies, and (c) to serve as potential therapeutics. However, the number of targets on the viral envelope spike for such antibodies has been limited. Here, we describe a set of human monoclonal antibodies that define what is, to the best of our knowledge, a previously undefined target on HIV Env. The antibodies recognize a glycan-dependent epitope on the prefusion conformation of gp41 and unambiguously distinguish cleaved from uncleaved Env trimers, an important property given increasing evidence that cleavage is required for vaccine candidates that seek to mimic the functional HIV envelope spike. The availability of this set of antibodies expands the number of vaccine targets on HIV and provides reagents to characterize the native envelope spike.
Subject(s)

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: HIV Antibodies / HIV Envelope Protein gp41 / Antibodies, Neutralizing / Antibodies, Monoclonal Limits: Humans Language: En Journal: Immunity Journal subject: ALERGIA E IMUNOLOGIA Year: 2014 Document type: Article

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: HIV Antibodies / HIV Envelope Protein gp41 / Antibodies, Neutralizing / Antibodies, Monoclonal Limits: Humans Language: En Journal: Immunity Journal subject: ALERGIA E IMUNOLOGIA Year: 2014 Document type: Article
...